Sanctuary Advisors LLC Acquires New Shares in Smith & Nephew SNATS, Inc. $SNN

Sanctuary Advisors LLC acquired a new position in Smith & Nephew SNATS, Inc. (NYSE:SNN) in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 33,468 shares of the medical equipment provider’s stock, valued at approximately $2,099,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in SNN. Clearstead Trust LLC bought a new stake in shares of Smith & Nephew SNATS in the 2nd quarter valued at about $25,000. Addison Advisors LLC bought a new position in shares of Smith & Nephew SNATS during the second quarter valued at approximately $43,000. Allworth Financial LP purchased a new position in Smith & Nephew SNATS during the second quarter valued at approximately $48,000. Garner Asset Management Corp bought a new position in Smith & Nephew SNATS in the fourth quarter worth approximately $27,000. Finally, Arax Advisory Partners raised its stake in Smith & Nephew SNATS by 142.6% in the fourth quarter. Arax Advisory Partners now owns 968 shares of the medical equipment provider’s stock worth $32,000 after buying an additional 569 shares in the last quarter. 25.64% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several analysts have issued reports on the company. The Goldman Sachs Group reaffirmed a “buy” rating on shares of Smith & Nephew SNATS in a research report on Monday, May 25th. JPMorgan Chase & Co. restated a “neutral” rating on shares of Smith & Nephew SNATS in a research note on Thursday, August 6th. Kepler Capital Markets downgraded Smith & Nephew SNATS from a “buy” rating to a “hold” rating in a research report on Thursday, June 4th. Canaccord Genuity Group cut their target price on Smith & Nephew SNATS from $32.00 to $30.00 and set a “hold” rating on the stock in a research note on Monday, May 11th. Finally, Wall Street Zen upgraded Smith & Nephew SNATS from a “hold” rating to a “buy” rating in a research note on Monday. Two analysts have rated the stock with a Buy rating, six have assigned a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $30.93.

Smith & Nephew SNATS Trading Up 0.3%

Smith & Nephew SNATS stock opened at $29.32 on Thursday. Smith & Nephew SNATS, Inc. has a 1-year low of $28.56 and a 1-year high of $38.79. The business has a fifty day moving average price of $30.26 and a 200-day moving average price of $31.74. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.14 and a quick ratio of 1.11.

Smith & Nephew SNATS Announces Dividend

The firm also recently declared a dividend, which will be paid on Friday, November 6th. Stockholders of record on Friday, October 2nd will be paid a dividend of $0.312 per share. The ex-dividend date is Friday, October 2nd. This represents a dividend yield of 205.0%.

Smith & Nephew SNATS Company Profile

Smith & Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing.

In its orthopaedics business, Smith & Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair.